Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure.

A clinical trial, NCT06507657, is being conducted to examine the impact of empagliflozin on left atrial function in adults at risk for heart failure. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to reduce cardiovascular disease (CVD) events, including heart failure. Empagliflozin, a medication primarily used for type 2 diabetes, has demonstrated promising results in previous studies. The trial will involve 80 participants and will be a placebo-controlled, double-blinded, randomized pilot study. The document provides information about the study, including its purpose, methodology, and eligibility criteria for participants. [Extracted from the article]